menu
    • menu
    [{"orgOrder":0,"company":"Mariana Oncology","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Series B Financing","leadProduct":"MC-339","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mariana Oncology","amount2":0.17999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Mariana Oncology \/ Deep Track Capital","highestDevelopmentStatusID":"4","companyTruncated":"Mariana Oncology \/ Deep Track Capital"},{"orgOrder":0,"company":"Mariana Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"MC-339","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mariana Oncology","amount2":1.75,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.75,"dosageForm":"","sponsorNew":"Mariana Oncology \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Mariana Oncology \/ Novartis Pharmaceuticals Corporation"}]

    Find Clinical Drug Pipeline Developments & Deals by Mariana Oncology

    Menu

    Mariana Oncology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mariana Oncology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Mariana Oncology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MC-339

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $1,750.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Novartis to Acquire Mariana Oncology to Advance Precision Radiopharmaceuticals for Cancer

                            Details : Through the acquisition Novartis expand its radiopharmaceutical pipeline and platform by including Mariana Oncology’s lead program, MC-339, a novel radioligand therapy for small-cell lung cancer.

                            Brand Name : MC-339

                            Molecule Type : Peptide

                            Upfront Cash : $1,000.0 million

                            May 02, 2024

                            Lead Product(s) : MC-339

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $1,750.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mariana Oncology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Mariana Oncology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MC-339

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Deep Track Capital

                            Deal Size : $175.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Mariana Oncology Announces $175 Million Series B Financing

                            Details : The proceeds will support the advancement of Mariana's novel portfolio of precision, next-generation radiopharmaceuticals including its lead candidate, MC-339, a peptidic small molecule engineered to carry an actinium payload for the targeted radiopharma...

                            Brand Name : MC-339

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            September 07, 2023

                            Lead Product(s) : MC-339

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Deep Track Capital

                            Deal Size : $175.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth